{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T02:49:52Z","timestamp":1768618192833,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T00:00:00Z","timestamp":1354147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology Research"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The aims of this study are to assess the antiviral effects, safety and telaprevir (<jats:styled-content style=\"fixed-case\">TVR<\/jats:styled-content>) pharmacokinetics in two cohorts given<jats:styled-content style=\"fixed-case\">TVR<\/jats:styled-content>every 8\u2009h (q8h) at doses of 500\u2009mg and 750\u2009mg with peginterferon\u2010\u03b1\u20102b and ribavirin in chronic hepatitis<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty chronic hepatitis<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>(<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) patients with genotype 1b in high viral loads were randomly assigned to two<jats:styled-content style=\"fixed-case\">TVR<\/jats:styled-content>\u2010based regimens of 750\u2009mg q8h (group<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>) and 500\u2009mg q8h (group<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>) in combination with peginterferon\u2010\u03b1\u20102b and ribavirin for 12\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Although the difference was not statistically significant other than trough concentration (<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content><jats:sub>trough<\/jats:sub>) at week 4, the parameters of maximum concentration (<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content><jats:sub>max<\/jats:sub>), the area under the concentration time curve (<jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content><jats:sub>0\u2013\u221e<\/jats:sub>) and<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content><jats:sub>trough<\/jats:sub>tended to be higher in group<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>than those in group<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>. The antiviral effects were similar in the two groups (sustained virological response rates [<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>], 40% in group<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>, 50% in group<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>). The discontinuation rates by anemia were 30% in group<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>and 20% in group<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>. Serum creatinine concentrations were lower in group<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>than those in group A.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although the exposure to<jats:styled-content style=\"fixed-case\">TVR<\/jats:styled-content>tended to be lower in 500\u2009mg q8h than that in 750\u2009mg q8h, the<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>rates in both groups were similar. The result suggests that the 500\u2009mg q8h dose may be one option for treatment. In addition, the present findings indicate that the development of adverse events which increase with a<jats:styled-content style=\"fixed-case\">TVR<\/jats:styled-content>\u2010based regimen, specifically anemia and creatinine, could be avoided by dose adjustment of<jats:styled-content style=\"fixed-case\">TVR<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hepr.12009","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T13:27:19Z","timestamp":1354195639000},"page":"691-701","source":"Crossref","is-referenced-by-count":17,"title":["Exploratory study on telaprevir given every 8\u2009h at 500\u2009mg or 750\u2009mg with peginterferon\u2010alpha\u20102b and ribavirin in hepatitis<scp>C<\/scp>patients"],"prefix":"10.1111","volume":"43","author":[{"given":"Fumitaka","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Sezaki","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Seko","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuji","family":"Arase","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Mineta","sequence":"additional","affiliation":[{"name":"Research Institute for Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiyo","family":"Watahiki","sequence":"additional","affiliation":[{"name":"Research Institute for Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Research Institute for Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Nakayasu","sequence":"additional","affiliation":[{"name":"Development Division Mitsubishi Tanabe Pharma Corporation Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Development Division Mitsubishi Tanabe Pharma Corporation Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Aoki","sequence":"additional","affiliation":[{"name":"Development Division Mitsubishi Tanabe Pharma Corporation Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichimaro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Development Division Mitsubishi Tanabe Pharma Corporation Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,11,29]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Hepatitis C. (Global Alert and Response, 2002)","author":"World Health Organization","year":"2002"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360704"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff LB","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014463"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.07.016"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01528.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807650"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.07.013"},{"key":"e_1_2_6_12_1","unstructured":"Antiviral Products Advisory Committee.Telaprevir NDA briefing document. Available at:http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM252561. Accessed October 2012."},{"key":"e_1_2_6_13_1","unstructured":"Telaprevir NDA 201\u2010917 vertex pharmaceuticals. FDA Advisory Committee Briefing.Document. Available at:http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM252562. Accessed October 2012."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2009.00548.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000086064"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.09.019"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118025"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601113340203"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100380170047"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1206"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24058"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.046"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir210"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23690"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200402000-00004"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01004.x"}],"container-title":["Hepatology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhepr.12009","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hepr.12009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T23:21:40Z","timestamp":1745364100000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hepr.12009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1111\/hepr.12009"],"URL":"https:\/\/doi.org\/10.1111\/hepr.12009","archive":["Portico"],"relation":{},"ISSN":["1386-6346","1872-034X"],"issn-type":[{"value":"1386-6346","type":"print"},{"value":"1872-034X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]}}}